## **Outpatient Treatments for COVID-19 in Children**

Outpatient treatments for mild-moderate COVID-19 are available for patients who meet the following general criteria:

- An underlying risk factor for progression to severe disease, available on the NCH website
- Symptoms of COVID-19 and a positive viral test for SARS-CoV-2 (including home tests)
- Not hospitalized due to COVID-19, requiring oxygen therapy due to COVID-19, or requiring an increase in oxygen flow rate due to COVID-19 (for those on chronic oxygen therapy)

Drug Name	Minimum Age	Minimum Weight	Additional Criteria	Contraindications/ Precautions	How to Access†
Paxlovid (nirmatrelvir & ritonavir)	12 years	40 kg	<ul> <li>Able to start treatment within <u>5</u> days of symptom onset</li> <li>Able to swallow pills whole</li> </ul>	Contraindications:  Transplant & currently on immunosuppressive therapy Pregnancy Malabsorption Many drug-drug interactions	Call Physician Direct Connect (614-355-0221) and speak to an ID physician or prescribe to retail pharmacy or NCH Blue pharmacy <sup>†</sup>
IV Remdesivir (3-day course)	28 days	3 kg	Able to start treatment within <u>7</u> days of symptom onset	Precautions:  Transaminase elevation  PT prolongation	Call Physician Direct Connect (614-355-0221) and speak to an ID physician

<sup>&</sup>lt;sup>†</sup>For NCH inpatients with COVID-19 but NOT hospitalized because of COVID-19, and who are otherwise eligible for outpatient therapy, contact the ID consult team. If treatment recommended, bebtelovimab and remdesivir can be ordered in Epic; for Paxlovid, work with clinical pharmacist to complete review of potential drug-drug interactions and facilitate ordering.

Review contraindications before prescribing. If obtained through ID via Physician Direct Connect, pharmacy review occurs routinely prior to prescribing.

<sup>&</sup>lt;sup>†</sup>Clinicians may prescribe Paxlovid to <u>retail pharmacies</u> or NCH Blue pharmacy without speaking to NCH ID. All prescriptions written in NCH Epic will undergo pharmacist review prior to transmission to the pharmacy.